Vidaza azacitidine: Phase III started

Celgene disclosed in its 3Q10 earnings that it began an open-label, international Phase III trial to evaluate once-daily 75 mg/m 2 subcutaneous Vidaza for the first 7 days of a 28-day cycle vs. standard of care (SOC) in 480 elderly patients with newly diagnosed AML. SOC includes intensive chemotherapy with cytarabine and anthracycline plus best supportive care (BSC), low-dose cytarabine plus BSC or BSC alone. ...